AOD9604 5mg*10vials

▎AOD 9604 Research

What is the research background of AOD 9604?

AOD 9604 is a peptide composed of the C-terminal fragment of human growth hormone (hGH), specifically the amino acid sequence 177 – 191, with an additional tyrosine residue at the N-terminus of the peptide.

The relationship between AOD 9604, growth hormone, and obesity treatment is as follows. Although human growth hormone (hGH) has the potential to treat obesity, safety issues limit its long-term use. As a C-terminal fragment of hGH, AOD 9604 is considered to potentially play a role in treating obesity without causing the negative effects of hGH. Studies have found that both hGH and AOD 9604 can induce weight loss and increase lipolytic sensitivity after long-term treatment in mice. One possible mechanism is through interaction with the β-adrenergic pathway, especially with the beta (3)-adrenergic receptors (β3-AR)^[1] .

Both hGH and AOD 9604 can reduce the body weight and body fat of obese mice, and this result is related to the increased expression level of β3-AR RNA, the main lipolytic receptor in adipocytes. Importantly, both hGH and AOD 9604 can increase the suppressed β3-AR RNA levels in obese mice to a level comparable to that in lean mice^[1] .

However, in β3-AR knockout mice, long-term use of hGH and AOD 9604 failed to produce the weight changes and increased lipolysis observed in wild-type control mice. But in acute experiments, AOD 9604 could increase the energy consumption and fat oxidation in β3-AR knockout mice ^[1].

Treatment of osteoarthritis: Intra-articular injection of AOD 9604 has shown certain curative effects in a rabbit model of osteoarthritis. The research by Kwon Dong Rak and Park Gi Young shows that ultrasound-guided intra-articular injection of AOD 9604 enhances cartilage regeneration, and the combined injection of AOD 9604 and hyaluronic acid (HA) is more effective than using HA or AOD 9604 alone^[2] .

AOD 9604 has been reported to mimic the lipolytic properties of growth hormone without the side effect of inducing diabetes. Therefore, it may be used as a performance-enhancing drug and is prohibited by the World Anti-doping Agency (WADA)^[3].

The research background of AOD 9604 mainly stems from the contradiction between the potential of human growth hormone in treating obesity and its safety issues. At the same time, with the increase in metabolic diseases, its potential role in improving metabolic health and its safety have become the focus of research.

What are the characteristics and advantages of the mechanism of action of AOD 9604 in weight loss and metabolic regulation?

First of all, in terms of lipolysis, AOD 9604 significantly enhances the sensitivity of lipolysis by activating the β3-adrenergic receptor (β3-AR) pathway of adipocytes. This activation enables adipocytes to more effectively break down stored triglycerides into free fatty acids and glycerol, thus promoting the decomposition and utilization of fat to provide energy for the body. This process not only helps to reduce the accumulation of body fat but also improves the body’s fat distribution, reduces the proportion of visceral fat, and thus reduces the risk of various obesity-related diseases, such as cardiovascular diseases and type 2 diabetes.

Secondly, AOD 9604 also performs well in inhibiting lipogenesis. It can prevent the fat from ingested food from being converted into body fat by regulating the expression of genes related to lipogenesis. Specifically, AOD 9604 can inhibit the activity of key lipogenic enzymes such as fatty acid synthase, thereby reducing the synthesis and storage of fatty acids. This inhibitory effect helps to reduce the proliferation and differentiation of adipocytes and prevent the excessive expansion of adipose tissue, thus achieving the effect of weight loss. At the same time, this inhibitory effect can also help maintain the balance of the body’s fat metabolism and avoid metabolic disorders caused by excessive fat accumulation.

In terms of metabolic regulation, the role of AOD 9604 is more complex and comprehensive. It can shift the body’s energy metabolism from glucose metabolism to fat metabolism, and this shift is of great significance for weight loss and improving metabolic health. By increasing the oxidative decomposition of fatty acids, AOD 9604 provides more energy sources for the body and reduces the dependence on glucose metabolism. This metabolic regulation not only helps to increase the basal metabolic rate, making the body consume more energy at rest, but also improves insulin sensitivity, promotes the uptake and utilization of glucose, and thus maintains the stability of blood sugar levels. In addition, this metabolic regulation effect also helps to reduce the deposition of fat in organs such as the liver, preventing and improving metabolic diseases such as fatty liver.

Finally, AOD 9604 has unique advantages in reducing insulin resistance. Compared with the complete growth hormone, AOD 9604 removes the side effects that may lead to insulin resistance and increased blood sugar. This improvement makes AOD 9604 safer during the treatment process and will not have an adverse impact on blood sugar levels. This has important clinical significance for obese patients, especially those with insulin resistance or abnormal blood sugar. AOD 9604 can not only help them lose weight but also improve insulin sensitivity, reduce the risk of developing type 2 diabetes, and improve the overall metabolic health level.

In conclusion, AOD 9604 exerts its effects on weight loss and metabolic regulation through multiple mechanisms of action, providing a new choice and hope for the treatment of obesity and metabolic diseases.

What are the specific links through which AOD 9604 affects fat metabolism?

Interaction with the β-adrenergic pathway: Studies have shown that hGH and the lipolytic fragment AOD 9604 synthesized from its C-terminal can induce weight loss and increase lipolytic sensitivity after long-term treatment in mice^[4] . One possible mechanism is through interaction with the β-adrenergic pathway, especially with the β₃-adrenergic receptor (β₃-AR). In obese mice, hGH and AOD 9604 can increase the expression level of β₃-AR RNA and can increase the suppressed β₃-AR RNA levels in obese mice to a level comparable to that in lean mice. However, long-term treatment of β₃-AR knockout mice with hGH and AOD 9604 failed to produce the weight changes and increased lipolysis observed in wild-type control mice. But in acute experiments, AOD 9604 could increase the energy consumption and fat oxidation in β₃-AR knockout mice. This indicates that the lipolytic effects of hGH and AOD 9604 are not directly mediated by β₃-AR, although both can increase the expression of β₃-AR, which may subsequently help enhance lipolytic sensitivity.

Increasing fat oxidation and stimulating lipolysis: In obese (ob/ob) and lean C57BL/6J mice, the chronic effects of human growth hormone (hGH) and AOD 9604 (the C-terminal fragment of hGH) can be observed on body weight, energy balance, and substrate oxidation rates. Both hGH and AOD 9604 significantly reduced the weight gain of obese mice, which was related to the increased fat oxidation in the body and the increased plasma glycerol levels (an indicator of lipolysis). Unlike hGH, AOD 9604 does not cause hyperglycemia or reduce insulin secretion. AOD 9604 does not compete with the hGH receptor and does not induce cell proliferation like hGH. This further confirms the concept of hGH as a prohormone, indicating that the fragment of hGH can act in a way different from the traditional hGH stimulation pathway^[4] .

What is the effect of AOD 9604 on the liver?

The effect of AOD 9604 on the liver is mainly reflected in its regulatory effect on fat metabolism. As a synthetic polypeptide that mimics the lipolytic functional domain of human growth hormone (hGH), AOD 9604 can promote lipolysis, inhibit lipogenesis, and shift the body’s energy metabolism from glucose metabolism to fat metabolism. This mechanism of action helps to reduce the accumulation of fat in the liver, thus providing a certain degree of protection to the liver. For metabolic diseases such as fatty liver, the weight loss and metabolic regulation effects of AOD 9604 may help improve the fat metabolism status of the liver, reduce the burden on the liver, and thus improve liver function. However, there are currently few direct studies on the effect of AOD 9604 on the liver. The above effects are mainly speculated based on its effect on fat metabolism, and more scientific research is still needed to verify the specific liver protection effects and mechanisms of action.

What is the significance of AOD 9604?

AOD 9604 is a synthetic polypeptide that mimics the lipolytic functional domain of human growth hormone (HGH), and its medical application value is significant. In the treatment of obesity and metabolic diseases, AOD 9604 can effectively promote lipolysis, inhibit lipogenesis, and regulate the body’s metabolic process, helping obese patients lose weight, improve body composition, and has potential application value in the treatment of metabolic diseases such as fatty liver. Compared with the complete growth hormone, it removes the side effects that may lead to insulin resistance and increased blood sugar, so it is safer during the treatment process and is suitable for a wider range of patients.

AOD 9604 has important significance in the field of drug research and development. As a weight loss drug with a unique mechanism of action, it provides a new choice for the treatment of obesity, demonstrates the potential of polypeptide drugs in treating metabolic diseases, and provides new ideas and research directions for the subsequent development of more safe and effective weight loss drugs. In addition, the synthesis and research of AOD 9604 have promoted the development of the field of polypeptide drugs, verified the feasibility of polypeptide drugs in mimicking and regulating specific physiological functions in the body, and provided valuable experience for the design, synthesis, and optimization of polypeptide drugs.

In promoting a healthy lifestyle, AOD 9604 can be used as an auxiliary means to help people control their weight and maintain a healthy state. Obesity is a serious problem in modern society, and its weight loss effect can provide additional support for people who have difficulty losing weight through simple diet and exercise. At the same time, by regulating fat metabolism, it helps to improve the body’s metabolic health status, reduce blood lipid levels, reduce the deposition of fat in blood vessels, reduce the risk of metabolic-related diseases such as cardiovascular diseases, and improve the quality of life.

AOD 9604 also plays an important role in promoting basic research. Its research helps to deeply explore the mechanism of action of human growth hormone, especially its specific role and signaling pathway in the regulation of fat metabolism. Through the research on AOD 9604, scientists can better understand how growth hormone exerts its physiological functions through the interaction between specific domains and receptors, and how these functions change under different physiological and pathological conditions. In addition, AOD 9604 can be used as a research tool for research related to fat metabolism, helping scientists study the processes of fat decomposition, generation, and cell signal transduction, revealing the molecular mechanisms and regulatory networks of fat metabolism, and providing a theoretical basis for the development of treatment methods and drugs for abnormal fat metabolism.

Journal Author

Heffernan, M A  is affiliated with the University of Limerick and is active in several academic disciplines. These include Endocrinology & Metabolism, where research might focus on hormonal functions and metabolic processes within the body. In Polymer Science, their work could involve the study of polymer materials, their synthesis, properties, and applications. Physiology would cover the functions and processes of living organisms, while Nutrition & Dietetics pertains to the science of food, nutrition, and dietary practices.

Scientific Journal Author

Heffernan’s research may explore the intersections of these fields, such as developing polymer-based drug delivery systems for metabolic disorders or studying the physiological impacts of nutritional interventions using advanced material science techniques. Their work contributes to a deeper understanding of biological processes and the development of innovative solutions in healthcare and material science. Heffernan, M A is listed in the reference of citation [4].

▎Relevant Citations

[1] Heffernan M, Summers R J, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice[J]. Endocrinology, 2001,142(12):5182-5189.DOI:10.1210/en.142.12.5182.

[2] Kwon D R, Park G Y. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model[J]. Annals of Clinical and Laboratory Science, 2015,45(4):426-432. http://www.annclinlabsci.org/content/45/4/426.long

[3] Cox H D, Smeal S J, Hughes C M, et al. Detection and in vitro metabolism of AOD9604[J]. Drug Testing and Analysis, 2015,7(1):31-38.DOI:10.1002/dta.1715.

[4] Heffernan M A, Thorburn A W, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment[J]. International Journal of Obesity, 2001,25(10):1442-1449.DOI:10.1038/sj.ijo.0801740.

[5]  Ng F M, Sun J, Sharma L, et al. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone[J]. Hormone Research in Paediatrics, 2001,53:274-278. DOI: 10.1159/000053183

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.